Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. World J Clin Oncol 2025; 16(9): 108585 [PMID: 41024830 DOI: 10.5306/wjco.v16.i9.108585]
Corresponding Author of This Article
Hiroki Goto, MD, PhD, Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan. hgoto20@kumamoto-u.ac.jp
Research Domain of This Article
Hematology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Sep 24, 2025 (publication date) through Oct 25, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. World J Clin Oncol 2025; 16(9): 108585 [PMID: 41024830 DOI: 10.5306/wjco.v16.i9.108585]
Hiroki Goto, Mariko Takano, Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, Japan
Yoshioki Shiraishi, Radioisotope Center, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, Japan
Sudjit Luanpitpong, Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Author contributions: Goto H performed the majority of the writing and prepared the Figures and Tables; Takano M and Shiraishi Y provided input in writing the paper and performed writing; Luanpitpong S provided input in writing the paper and was involved in preparing Figure 2.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroki Goto, MD, PhD, Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan. hgoto20@kumamoto-u.ac.jp
Received: April 18, 2025 Revised: May 22, 2025 Accepted: August 4, 2025 Published online: September 24, 2025 Processing time: 158 Days and 15.9 Hours
Core Tip
Core Tip: Fluorine-18 (18F)-fluorodeoxyglucose (FDG)-PET is commonly used to detect residual tumor cells and evaluate treatment responses in hematologic malignancies. However, as FDG uptake reflects glucose metabolism, it does not accurately indicate the presence of tumor cells expressing specific antigens. Recent studies have introduced immuno-PET, which labels antibodies or other immune-targeting molecules with positron-emitting radionuclides, as a promising alternative for visualizing tumor distribution and assessing therapeutic responses. This technique provides a specific imaging approach. In this minireview, we highlight recent progress in immuno-PET and discuss its future clinical applications in the management of hematologic malignancies.
